DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1781)

Axial Spondyloarthritis | Landscape & Forecast | Disease Landscape & Forecast

Axial Spondyloarthritis | Landscape & Forecast | Disease Landscape & Forecast

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

The axial spondyloarthritis (AxSpA) market boasts seven different biologics representing two distinct drug classes, the blockbuster tumor necrosis factor alpha (TNF-α) inhibitors (Amgen’s Enbrel, AbbVie’s Humira, Janssen’s Remicade, Simponi/Simponi Aria, and UCB’s Cimzia) and one interleukin 17 (IL-17) inhibitor, Novartis’s Cosentyx. The TNF- α inhibitors are the most widely prescribed biologics in AxSpA patients refractory to NSAIDs. However, they face a competitive threat both from the launch of cost-effective biosimilars and from the growing IL-17 class, which offers efficacy data that have met more-stringent clinical trial end points. Some manufacturers are also continuing to pursue the first FDA approval for the non-radiographic AxSpA subpopulation. With the impending entry of additional IL-17 inhibitors (Eli Lilly’s Taltz and Kyowa Hakko Kirin’s Lumicef) and Phase III clinical trials for the first oral targeted therapy for this indication, Pfizer’s Jak inhibitor Xeljanz, marketers are faced with increasing challenges to differentiate their therapies and to gain market uptake.

Key questions answered:

  • How large is the treatable AxSpA population and how will diagnosis/drug-treatment rates change over time?
  • What are interviewed experts’ insights on current treatment options? What clinical needs remain unfulfilled?
  • What pipeline products are most promising, and what sales/uptake could they secure in AxSpA?
  • What therapies of note are progressing in earlier phases?
  • What are the drivers and constraints in the AxSpA market, and how will the market evolve over the forecast period?

Already a Client? Log in to access this report.

  • Pub Date: July 2018
  • Author(s): Maria Genco, Ph.D; Mudasir Khan, M.P.H
  • Maria Genco, is an analyst on the Immune and Inflammatory Disorders group at Decision Resources Group, primarily focusing on rheumatoid arthritis and axial spondyloarthritis. She has authored market research reports on the RA disease landscape and commercial outlook of drugs, unmet needs in RA, and market access and reimbursement for RA targeted therapies. Prior to joining Decision Resources, Dr. Genco received her and in neuroscience from Brandeis University and a in neuroscience from Wellesley College.

  • Mudasir works as an associate epidemiologist within the epidemiology team at Decision Resources Group. He specializes in developing epidemiological forecasts for multiple indications within the DRG syndicated portfolio. Mudasir holds a masters in public health specializing in epidemiology from TISS, Mumbai.

Become a DRG client

Recent reports:
You may also be interested in: